FOS and cancer: In CD4+ T cells, Fe-EGCG@RSL3 treatment diminished Jun/Fos-expressing stress response state T cells, which has been similarly identified as an immunotherapy resistance-related CD4+ T-cell subpopulation in single-cell analyses across 16 types of human cancers [22].